Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 871 to 885 of 1517 results for patients and public

  1. Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]

    In development Reference number: GID-TA11658 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]

    In development Reference number: GID-TA11801 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]

    In development Reference number: GID-TA11866 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Acalabrutinib with R-CHOP for untreated non-germinal centre B-cell diffuse large B-cell lymphoma [ID6614]

    Awaiting development Reference number: GID-TA11811 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Gemcitabine intravesical delivery system for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6658]

    Awaiting development Reference number: GID-TA11868 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Ondansetron for treating alcohol-use disorder [ID6341]

    Awaiting development Reference number: GID-TA11375 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Transvenous embolisation for treating cerebrospinal fluid-venous fistula associated with spontaneous intracranial hypotension

    In development Reference number: GID-IPG10318 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  8. Percutaneous insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock

    In development Reference number: GID-IPG10404 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  9. Apraglutide for treating short bowel syndrome [ID6533]

    In development Reference number: GID-TA11695 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]

    In development Reference number: GID-TA11716 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]

    In development Reference number: GID-TA11818 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]

    In development Reference number: GID-TA11765 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]

    In development Reference number: GID-TA11859 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Gemcitabine intravesical delivery system for treating recurrent high-risk papillary non-muscle-invasive bladder after BCG [ID6657]

    Awaiting development Reference number: GID-TA11872 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465]

    Awaiting development Reference number: GID-TA11703 Expected publication date:  25 February 2026

    Technology appraisal guidance
    Awaiting development